TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05263219
Drug: dTACE-HAIC protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Study: NCT05263219
Drug: HAIC protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Study: NCT05368142
Drug: Nocardia rubra Cell Wall Skeleton
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocardia rubra cell wall skeleton for external application
Study: NCT03541889
Drug: FLT imaging and TK1 blood measurements
Normalized name: SUS SCROFA BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
Study: NCT05259033
Drug: IcoSema
Approvals — FDA: no, EMA: no, PMDA: no
Description: IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month.
Study: NCT05050136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules matched to study drug without the active pharmaceutical ingredient
Study: NCT06143059
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile, 95% ethanol will be administered through IV infusion
Study: NCT05113290
Drug: Recombinant Human Adenovirus Type 5 injection
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
Study: NCT06031610
Drug: drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
Study: NCT06466135
Drug: WAL0921
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
Study: NCT06466135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
Study: NCT05384678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Placebo (saline infusion) will be administered.
Study: NCT05384678
Drug: N,N-Dimethyltryptamine (108 mg) + dose titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
Study: NCT05838716
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05769608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks
Study: NCT04586023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
Study: NCT05960851
Drug: LY3871801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05960851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06313047
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
Study: NCT06397001
Drug: nL-SAA1-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antisense oligonucleotide
Study: NCT06464146
Drug: IN fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IN fentanyl (1.5 µg/kg)
Study: NCT06464146
Drug: NaCl 0,9 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
Study: NCT05614102
Drug: BAY2965501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral application
Study: NCT05853835
Drug: LPX-TI641
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
Study: NCT04822766
Drug: Best chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
Study: NCT05370521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active dosage form taken once daily.
Study: NCT06259123
Drug: [177Lu]Lu-PSMA I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
Study: NCT05485831
Drug: Epidiolex 100 mg/mL Oral Solution
Normalized name: Epidiolex 100 MG/ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed in routine clinical practice in Italy.
Study: NCT05579626
Drug: high-intensity statin arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: •high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
Study: NCT05382559
Drug: ASP3082
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT05382559
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Infusion
Study: NCT05382559
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Infusion
Study: NCT05249101
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
Study: NCT05299242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline \[0.9% NaCl\]
Study: NCT05158608
Drug: Post-transplantation Cyclophosphamide at dose 25 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
Study: NCT05158608
Drug: Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
Study: NCT05922683
Drug: Vivomixx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm.
Study: NCT06413498
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT04781140
Drug: 100mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg SPN-812 will be administered once daily and compared to Placebo
Study: NCT04781140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once daily
Study: NCT05861648
Drug: Folic Acid Oral Tablet
Normalized name: folic acid Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: Folic acid 2.5mg/day
Study: NCT05602090
Drug: 4 IU of recombinant GH (Somatotropin )
Normalized name: ADAMTS13, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU of recombinant GH
Study: NCT06236425
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
Study: NCT05344911
Drug: Propofol combined with remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
Study: NCT06569056
Drug: HRS-8427 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Study: NCT06565572
Drug: nL-FLVC-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
Study: NCT06237309
Drug: REGN5381
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous (IV) infusion
Study: NCT06237309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV infusion
Study: NCT06567041
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT06567041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT06556511
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.
Study: NCT06556511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered with standard therapy in the placebo group for a period of 10 days.
Study: NCT05825781
Drug: Perjeta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.
Study: NCT05247593
Drug: Dayingpian
Approvals — FDA: no, EMA: no, PMDA: no
Description: The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
Study: NCT05247593
Drug: conventional mood stabilizers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
Study: NCT00037622
Drug: ACH-126, 443 (beta-L-Fd4C)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04777409
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
Study: NCT06568094
Drug: SHR2554 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 tablets
Study: NCT04629248
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Study: NCT06280235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1569912
Study: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Study: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Study: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Study: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Normalized name: Rho(D) - Unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
Study: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
Study: NCT05123586
Drug: LY3361237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05123586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06125028
Drug: [18F]Fluorodeoxyglucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FDG i.v. injection.
Study: NCT05303064
Drug: OLZ/SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
Study: NCT04963088
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Study: NCT06529809
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
Study: NCT05916560
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05021263
Drug: IV Medications
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV magnesium sulfate, used to replete magnesium stores
Study: NCT06384222
Drug: Hyperpolarized [1-13C] pyruvate (HP 13C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05752149
Drug: CRGD-ZW800-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of study drug at lesat 2h prior to surgery
Study: NCT05708274
Drug: CPH + hand training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
Study: NCT05708274
Drug: CD-LD + hand training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
Study: NCT05708274
Drug: Placebo + hand training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
Study: NCT05067257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution
Study: NCT05753384
Drug: treatment of TKI in CML
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
Study: NCT04966832
Drug: XW10508
Approvals — FDA: no, EMA: no, PMDA: no
Description: XW10508 capsules or tablets
Study: NCT06511908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1 and 2 Control Intervention
Study: NCT05109728
Drug: [177Lu]Lu-DOTA-TATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.
Study: NCT05109728
Drug: [68Ga]Ga-DOTA-TATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
Study: NCT06122649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT04783766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- Tablets
Study: NCT06109558
Drug: LMV-12(HE003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cycle was 28 days. LMV-12(HE003), 30mg or 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.
Study: NCT06057519
Drug: Standard dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose rifampicin
Study: NCT04838613
Drug: [18F]CTT1057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
Study: NCT04838613
Drug: [68Ga]Ga-PSMA-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
Study: NCT06289998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are administrated to placebo in daily for 52 weeks.
Study: NCT05325099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injection) QOD x 3 times
Study: NCT05058924
Drug: Prophylactic low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.
Study: NCT05058924
Drug: Low molecular weight heparin and low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
Study: NCT05128409
Drug: XKH001 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
Study: NCT05128409
Drug: XKH001Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
Study: NCT04612751
Drug: AZD2936
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
Study: NCT04612751
Drug: MEDI5752
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
Study: NCT04612751
Drug: AZD7789
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
Study: NCT05027074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered via IV infusion
Study: NCT04901078
Drug: KNX100
Approvals — FDA: no, EMA: no, PMDA: no
Description: KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
Study: NCT05904912
Drug: Postoperative analgesia management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Study: NCT06155604
Drug: Standard maintenance therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)